1 hr. ago
Aug 4 (Reuters) - Pfizer on Tuesday slightly raised the lower end of its full-year revenue forecast after beating Wall Street estimates for second-quarter profit, driven by strong demand for blood thinner Eliquis.
Shares rose 1.8% to $25.5 in premarket trading.
Pfizer is banking on newer medicines to offset fading COVID revenue and reduce reliance on aging blockbuster drugs, while investors look for signs that its $10 billion purchase of Metsera can help establish a meaningful presence in the fast-growing obesity market.
The drugmaker, whose shares have fallen more than 50% from their pandemic-era peak, expects to return to stronger growth after 2028.
The U.S. drugmaker now expects annual sales of $60.5 billion to $62.5 billion, up from $59.5 billion to $62.5 billion forecast previously.
#forecast #drugmaker #reuters
Shares rose 1.8% to $25.5 in premarket trading.
Pfizer is banking on newer medicines to offset fading COVID revenue and reduce reliance on aging blockbuster drugs, while investors look for signs that its $10 billion purchase of Metsera can help establish a meaningful presence in the fast-growing obesity market.
The drugmaker, whose shares have fallen more than 50% from their pandemic-era peak, expects to return to stronger growth after 2028.
The U.S. drugmaker now expects annual sales of $60.5 billion to $62.5 billion, up from $59.5 billion to $62.5 billion forecast previously.
#forecast #drugmaker #reuters
12 hours ago
Bristol-Myers Squibb (BMY) shares opened higher on Monday following reports that the U.S. pharma giant held preliminary merger talks with UK rival AstraZeneca (AZN). If finalized, this reported transaction would create the world's largest drugmaker (by revenue) with a market cap approaching $400 billion.
The AstraZeneca rumors arrive at a time when Bristol-Myers stock is already in a massive uptrend, currently up more than 20% versus its low in mid-June.
General Motors vs. Ford: 1 Auto Giant Is Winning the EV Race
1 ******* anese Company Just Waved a Red Flag for Micron Stock. How to Play It Here.
Billionaire Ken Griffin Just Saved Situational Awareness, But Here's What a Rescue Call From Citadel Really Sounds Like — 'I… Heard the Grim Reaper's Scythe'
#bristol #myers #astrazeneca #giant
The AstraZeneca rumors arrive at a time when Bristol-Myers stock is already in a massive uptrend, currently up more than 20% versus its low in mid-June.
General Motors vs. Ford: 1 Auto Giant Is Winning the EV Race
1 ******* anese Company Just Waved a Red Flag for Micron Stock. How to Play It Here.
Billionaire Ken Griffin Just Saved Situational Awareness, But Here's What a Rescue Call From Citadel Really Sounds Like — 'I… Heard the Grim Reaper's Scythe'
#bristol #myers #astrazeneca #giant
5 days ago
This has been an active year in the mergers-and-acquisitions landscape across the biopharmaceutical industry. One of the more notable deals was Vertex Pharmaceuticals' acquisition of Crinetics Pharmaceuticals for $10 billion in cash (the transaction hasn't closed yet). This is the largest acquisition in Vertex Pharmaceuticals' history, and it will enable the biotech giant to gain several promising pipeline candidates in endocrinology. Could there be an even more massive acquisition on the horizon in the industry? It's hard to say for sure, but if there is, Viking Therapeutics (NASDAQ: VKTX) may be the acquisition target.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
According to the U.S. Centers for Disease Control and Prevention, a little over 70% of adults in the country are overweight or obese. Excess weight is linked to a range of serious health problems, including diabetes, heart disease, and many others. Recent breakthroughs are helping address the issue. Anti-obesity medicines are allowing patients to lose weight and reduce their risk of developing a range of conditions. But this market is still in its early stages and is projected to expand rapidly over the next decade. According to some estimates, it will be worth $190 billion in 2035, compared to just $79 billion last year.
No wonder, then, that many pharmaceutical giants are looking to dip their toes in this **** e. But discovering and developing brand-new therapies from scratch in any field is expensive and time-consuming. That's why well-established drugmakers often prefer to acquire companies with promising mid and late-stage **** ets. That's where Viking Therapeutics comes in. The company's portfolio includes subcutaneous VK2735, currently in phase 3 clinical trials, as well as an oral version of the drug, which should begin late-stage studies by year-end. Further, Viking Therapeutics developed VK3019, another weight-loss candidate, which recently started phase 1 clinical trials.
Viking Therapeutics has one of the more impressive weight-loss pipelines among mid-cap biotechs, making it a great target for a pharmaceutical leader looking to fast-track the process and land some highly promising anti-obesity pipeline candidates overnight. Viking Therapeutics' phase 3 studies for VK2735 are expected to be completed by late 2027. If the results are very strong, the company's shares will soar, making it a much more expensive acquisition target. So, if any pharmaceutical giant is going to make a move, it probably will be before then.
#viking #NVIDIA #weight #promising
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
According to the U.S. Centers for Disease Control and Prevention, a little over 70% of adults in the country are overweight or obese. Excess weight is linked to a range of serious health problems, including diabetes, heart disease, and many others. Recent breakthroughs are helping address the issue. Anti-obesity medicines are allowing patients to lose weight and reduce their risk of developing a range of conditions. But this market is still in its early stages and is projected to expand rapidly over the next decade. According to some estimates, it will be worth $190 billion in 2035, compared to just $79 billion last year.
No wonder, then, that many pharmaceutical giants are looking to dip their toes in this **** e. But discovering and developing brand-new therapies from scratch in any field is expensive and time-consuming. That's why well-established drugmakers often prefer to acquire companies with promising mid and late-stage **** ets. That's where Viking Therapeutics comes in. The company's portfolio includes subcutaneous VK2735, currently in phase 3 clinical trials, as well as an oral version of the drug, which should begin late-stage studies by year-end. Further, Viking Therapeutics developed VK3019, another weight-loss candidate, which recently started phase 1 clinical trials.
Viking Therapeutics has one of the more impressive weight-loss pipelines among mid-cap biotechs, making it a great target for a pharmaceutical leader looking to fast-track the process and land some highly promising anti-obesity pipeline candidates overnight. Viking Therapeutics' phase 3 studies for VK2735 are expected to be completed by late 2027. If the results are very strong, the company's shares will soar, making it a much more expensive acquisition target. So, if any pharmaceutical giant is going to make a move, it probably will be before then.
#viking #NVIDIA #weight #promising
6 days ago
July 29 (Reuters) - Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosis drugs stayed under pressure.
Investors are closely watching whether recent deals and newer products including its Alzheimer's drug Leqembi can reignite growth and help the company navigate mounting competition and pricing pressure across its aging multiple sclerosis portfolio.
Despite an upbeat quarter, Biogen cut its 2026 adjusted per-share profit forecast to between $12 and $13 from between $14.25 and $15.25 per share earlier, reflecting a $3.85 per share impact from acquisition-related charges.
Analysts were expecting 2026 profit of $12.72 per share, according to data compiled by LSEG.
The drugmaker said its $5.6 billion buyout of Apellis Pharmaceuticals earlier this year would account for an 85-cent-per-share hit to annual profit.
#biogen #quarter #july
Investors are closely watching whether recent deals and newer products including its Alzheimer's drug Leqembi can reignite growth and help the company navigate mounting competition and pricing pressure across its aging multiple sclerosis portfolio.
Despite an upbeat quarter, Biogen cut its 2026 adjusted per-share profit forecast to between $12 and $13 from between $14.25 and $15.25 per share earlier, reflecting a $3.85 per share impact from acquisition-related charges.
Analysts were expecting 2026 profit of $12.72 per share, according to data compiled by LSEG.
The drugmaker said its $5.6 billion buyout of Apellis Pharmaceuticals earlier this year would account for an 85-cent-per-share hit to annual profit.
#biogen #quarter #july
8 days ago
July 27, 2026 12:34 pm ET
Listen
(4 min)
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0849 ET – While many artificial-intelligence startups are exploring the technology’s potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.K. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn’t expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayudwsj.com)
#using #market
Listen
(4 min)
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0849 ET – While many artificial-intelligence startups are exploring the technology’s potential to find new drugs, AstraZeneca executives say the company is using it in other areas. AI is important in drug development, which entails large, expensive risks, AstraZeneca CEO Pascal Soriot says on a call with reporters. If AI can help fine-tune the design of a clinical trial to improve its chances of success, that could end up being a big benefit, Soriot says. The U.K. drugmaker is also using AI to improve productivity across the business, in areas like regulatory submissions, CFO Aradhana Sarin says on the call. AstraZeneca doesn’t expect any direct impact on jobs from AI as its portfolio continues to grow, Sarin adds. Shares rise 1.2%. (adria.calatayudwsj.com)
#using #market
8 days ago
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround.
The company on Monday announced that Michael Severino, an executive with leadership experience at startups as well as large drugmakers, will become its next CEO effective July 28. He'll replace longtime leader Doug Ingram, who in February announced plans to retire after a tumultuous run.
Severino has been working in the biopharmaceutical industry for more than two decades, including stops at AbbVie and Amgen. At AbbVie, Severino helped bring to market multiple drugs for psoriasis, arthritis, cancer and hepatitis C. At Amgen, he oversaw research and development as the company's senior vice president of development and corporate chief medical officer.
In 2022, Severino left AbbVie to run Tessera Therapeutics, a buzzy "gene writing" startup backed by Flagship Pioneering. Tessera recently brought its first drug prospect, a gene editing treatment for alpha-1 antitrypsin deficiency, into clinical testing. Last week, Tessera announced that Severino had joined a "commercial stage" biotech company and that former Merck & Co. executive Joseph Romanelli would serve as its next leader.
#abbvie #tessera #biopharma #amgen
Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround.
The company on Monday announced that Michael Severino, an executive with leadership experience at startups as well as large drugmakers, will become its next CEO effective July 28. He'll replace longtime leader Doug Ingram, who in February announced plans to retire after a tumultuous run.
Severino has been working in the biopharmaceutical industry for more than two decades, including stops at AbbVie and Amgen. At AbbVie, Severino helped bring to market multiple drugs for psoriasis, arthritis, cancer and hepatitis C. At Amgen, he oversaw research and development as the company's senior vice president of development and corporate chief medical officer.
In 2022, Severino left AbbVie to run Tessera Therapeutics, a buzzy "gene writing" startup backed by Flagship Pioneering. Tessera recently brought its first drug prospect, a gene editing treatment for alpha-1 antitrypsin deficiency, into clinical testing. Last week, Tessera announced that Severino had joined a "commercial stage" biotech company and that former Merck & Co. executive Joseph Romanelli would serve as its next leader.
#abbvie #tessera #biopharma #amgen
12 days ago
We can separate high-yield dividend stocks into two broad categories. The first group consists of companies with stable businesses that generate consistent cash flow and are very likely to continue paying -- and perhaps raising -- their dividends for the foreseeable future. The second are distressed corporations. They boast high yields because their share prices have fallen substantially, reflecting weak business fundamentals.
Many investors would put Pfizer (NYSE: PFE) in the second group. The drugmaker's shares have lost significant value over the past five years, as the company has failed to sustain the amazing success it achieved in the coronavirus market. However, there is much more to the story. Let's discuss why Pfizer's 7% forward yield is more sustainable than it appears at first glance.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Pfizer's revenue and earnings have declined over the past five years, while it has maintained and even increased its dividend. The company's payout ratio has soared as a result -- it is currently about 127%. That looks unsustainable. But Pfizer's cash payout ratio, a much better measure of whether the company can maintain its dividend program intact, looks less scary at 107.7%. Management is confident of the company's ability to sustain, and even increase, the payout moving forward. That isn't just wishful thinking: Pfizer could improve its business in the coming years and eventually post much stronger financial results.
Consider that Pfizer boasts highly promising programs in the pipeline that will yield brand-new approvals and label expansions. For instance, the company's Padcev is a cancer medicine that is currently one of its better-performing products. On July 10, Padcev earned approval for the treatment of muscle-invasive bladder cancer in combination with Merck's (NYSE: MRK) Keytruda. Padcev was granted the green light regardless of whether patients are eligible for Cisplatin, a chemotherapy drug for bladder cancer that is effective but comes with significant side effects. That's a big deal since many drugs for bladder cancer (including Padcev, initially) aren't approved regardless of Cisplatin eligibility.
#NVIDIA #yield #first
Many investors would put Pfizer (NYSE: PFE) in the second group. The drugmaker's shares have lost significant value over the past five years, as the company has failed to sustain the amazing success it achieved in the coronavirus market. However, there is much more to the story. Let's discuss why Pfizer's 7% forward yield is more sustainable than it appears at first glance.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Pfizer's revenue and earnings have declined over the past five years, while it has maintained and even increased its dividend. The company's payout ratio has soared as a result -- it is currently about 127%. That looks unsustainable. But Pfizer's cash payout ratio, a much better measure of whether the company can maintain its dividend program intact, looks less scary at 107.7%. Management is confident of the company's ability to sustain, and even increase, the payout moving forward. That isn't just wishful thinking: Pfizer could improve its business in the coming years and eventually post much stronger financial results.
Consider that Pfizer boasts highly promising programs in the pipeline that will yield brand-new approvals and label expansions. For instance, the company's Padcev is a cancer medicine that is currently one of its better-performing products. On July 10, Padcev earned approval for the treatment of muscle-invasive bladder cancer in combination with Merck's (NYSE: MRK) Keytruda. Padcev was granted the green light regardless of whether patients are eligible for Cisplatin, a chemotherapy drug for bladder cancer that is effective but comes with significant side effects. That's a big deal since many drugs for bladder cancer (including Padcev, initially) aren't approved regardless of Cisplatin eligibility.
#NVIDIA #yield #first
12 days ago
Updated July 23, 2026 4:59 pm ET
Listen
(3 min)
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1007 ET – Roche Holding is taking a disciplined approach to dealmaking since it doesn’t have its back against the wall to fill its drug pipeline, CEO Thomas Schinecker says on a call with **** ysts. The Swiss drugmaker is open to doing deals as long as they make sense from a financial perspective, Schinecker says. “We always make very detailed due diligence. We always have material-transfer agreements where we really test the molecules in our own hands…I’ve seen other companies lose a bit of discipline in this **** e,” he adds. Shares rise 4.4%. (adria.calatayudwsj.com)
#july
Listen
(3 min)
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1007 ET – Roche Holding is taking a disciplined approach to dealmaking since it doesn’t have its back against the wall to fill its drug pipeline, CEO Thomas Schinecker says on a call with **** ysts. The Swiss drugmaker is open to doing deals as long as they make sense from a financial perspective, Schinecker says. “We always make very detailed due diligence. We always have material-transfer agreements where we really test the molecules in our own hands…I’ve seen other companies lose a bit of discipline in this **** e,” he adds. Shares rise 4.4%. (adria.calatayudwsj.com)
#july
12 days ago
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
Will generic drugmakers bring manufacturing capacity to the US or will tariffs mean they'll simply hike the cost of the generic ibuprofen in your bathroom cabinet, adding wallet-ache to headache? We should find out … in the next year or two.
In a social media post, President Trump threatened companies Tuesday with 100% tariffs on imported generic drugs from August 2028, doubling to 200% one year later (months after the end of his second term) if they don't "reshore" manufacturing to the US.
Sign up for The Daily Upside at no cost for premium ****** ysis on all your favorite stocks.
READ ALSO: Blackstone's AI Bet Fuels Blowout Growth While Rivals Grapple With "Zombie Funds" and Defense Contractors Amass Record Backlogs as Military Spending Ramps Up
#sign #Manufacturing #cost
Will generic drugmakers bring manufacturing capacity to the US or will tariffs mean they'll simply hike the cost of the generic ibuprofen in your bathroom cabinet, adding wallet-ache to headache? We should find out … in the next year or two.
In a social media post, President Trump threatened companies Tuesday with 100% tariffs on imported generic drugs from August 2028, doubling to 200% one year later (months after the end of his second term) if they don't "reshore" manufacturing to the US.
Sign up for The Daily Upside at no cost for premium ****** ysis on all your favorite stocks.
READ ALSO: Blackstone's AI Bet Fuels Blowout Growth While Rivals Grapple With "Zombie Funds" and Defense Contractors Amass Record Backlogs as Military Spending Ramps Up
#sign #Manufacturing #cost
13 days ago
Finding a good dividend stock to buy at any given time usually isn't too tough. Finding one you can buy and hold forever, however, is a different story. The matter of longevity comes into play. You want to be sure the underlying company has the longevity required to not only continue paying its dividend, but to reliably raise its dividend payments at least in step with inflation. That's a taller order.
Nevertheless, these dividend names are out there. Here's a closer look at three of them.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Given the company's struggle since the easing of the COVID-19 pandemic undermined a fantastic but short-lived franchise, some investors might be surprised that drugmaker Pfizer (NYSE: PFE) earned a spot on this list. But it has, particularly since newcomers will be plugging into a healthy forward-looking dividend yield of 6.9%.
Although it'll be a while until investors can clearly see it, this pharmaceutical giant is developing multiple new profit centers. It acquired Seagen in 2023, for instance, largely for its oncology pipeline. This pipeline includes cancer-fighting Padcev, which was recently approved as a treatment for muscle-invasive bladder cancer when used in conjunction with Merck's Keytruda.
#Dividend #flashing
Nevertheless, these dividend names are out there. Here's a closer look at three of them.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Given the company's struggle since the easing of the COVID-19 pandemic undermined a fantastic but short-lived franchise, some investors might be surprised that drugmaker Pfizer (NYSE: PFE) earned a spot on this list. But it has, particularly since newcomers will be plugging into a healthy forward-looking dividend yield of 6.9%.
Although it'll be a while until investors can clearly see it, this pharmaceutical giant is developing multiple new profit centers. It acquired Seagen in 2023, for instance, largely for its oncology pipeline. This pipeline includes cancer-fighting Padcev, which was recently approved as a treatment for muscle-invasive bladder cancer when used in conjunction with Merck's Keytruda.
#Dividend #flashing
13 days ago
July 22 (Reuters) - Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in the fast-growing cell therapy market.
The acquisition gives Repligen access to BioLife's technology to preserve cells throughout the manufacturing process and the supply chain, as well as its portfolio of cell-processing tools and high-margin consumables business.
Larger peer Danaher on Tuesday signaled a recovery in demand for bioprocessing products, including equipment and consumables used to manufacture biologic drugs, as biotech and pharmaceutical companies ramp up spending after a broader slowdown in research spending and customer inventories in recent years.
The acquisition comes a month after German drugmaker Merck KGaA's $11.3 billion deal to buy Bio-Techne, underscoring growing interest in companies making tools for drug development.
BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen for each share, valuing the cell therapy tools supplier at $31 per share — a premium of about 6.2% to BioLife's last close.
#tools #billion #equipment #growing
The acquisition gives Repligen access to BioLife's technology to preserve cells throughout the manufacturing process and the supply chain, as well as its portfolio of cell-processing tools and high-margin consumables business.
Larger peer Danaher on Tuesday signaled a recovery in demand for bioprocessing products, including equipment and consumables used to manufacture biologic drugs, as biotech and pharmaceutical companies ramp up spending after a broader slowdown in research spending and customer inventories in recent years.
The acquisition comes a month after German drugmaker Merck KGaA's $11.3 billion deal to buy Bio-Techne, underscoring growing interest in companies making tools for drug development.
BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen for each share, valuing the cell therapy tools supplier at $31 per share — a premium of about 6.2% to BioLife's last close.
#tools #billion #equipment #growing
14 days ago
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Novartis said second-quarter sales inched upward, beating **** yst expectations for a decline as demand for newer products helped offset generic competition for its former top-selling heart medication Entresto.
At constant exchange rates, net sales increased 1% to $14.4 billion, Novartis said Tuesday. That beat the consensus estimate of about $13.7 billion, Jefferies **** yst Michael Leuchten wrote in a note to clients. Core operating income reached $5.94 billion, topping the consensus estimate of $5.31 billion. Leuchten had expected core operating income of $5.16 billion on sales of $13.8 billion.
The Swiss drugmaker highlighted increases of more than 30% for "priority brands" including Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio. Revenue from Entresto plunged by half to $1.18 billion in the period, moving the drug down to fourth place on the list of Novartis' most lucrative products.
Already buffeted by Entresto losses in the U.S., Novartis is looking ahead to one of the most daunting patent cliffs in the pharmaceutical industry over the next five years, affecting all four of its top-selling medicines in the second quarter. Entresto is set to lose exclusivity in Europe in 2028. After that, U.S. patent expirations follow for its biggest moneymaker, Cosentyx, in 2029 and both Kesimpta and Kisqali in 2031.
#billion #biopharma #dive
Novartis said second-quarter sales inched upward, beating **** yst expectations for a decline as demand for newer products helped offset generic competition for its former top-selling heart medication Entresto.
At constant exchange rates, net sales increased 1% to $14.4 billion, Novartis said Tuesday. That beat the consensus estimate of about $13.7 billion, Jefferies **** yst Michael Leuchten wrote in a note to clients. Core operating income reached $5.94 billion, topping the consensus estimate of $5.31 billion. Leuchten had expected core operating income of $5.16 billion on sales of $13.8 billion.
The Swiss drugmaker highlighted increases of more than 30% for "priority brands" including Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio. Revenue from Entresto plunged by half to $1.18 billion in the period, moving the drug down to fourth place on the list of Novartis' most lucrative products.
Already buffeted by Entresto losses in the U.S., Novartis is looking ahead to one of the most daunting patent cliffs in the pharmaceutical industry over the next five years, affecting all four of its top-selling medicines in the second quarter. Entresto is set to lose exclusivity in Europe in 2028. After that, U.S. patent expirations follow for its biggest moneymaker, Cosentyx, in 2029 and both Kesimpta and Kisqali in 2031.
#billion #biopharma #dive
16 days ago
Just when we thought things were going in a good direction, tensions in the Middle East escalated again. If things worsen, it may eventually impact broader equities. Even if that doesn't happen, it's always useful for investors to buy shares in solid, dividend-paying corporations that can perform relatively well -- and continue raising their payouts -- regardless of economic conditions.
Let's consider two excellent stocks that fit the bill: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Both are Dividend Kings, or companies with at least 50 consecutive years of dividend increases. Here's why they are among my favorite stocks in this elite group to buy right now.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie, a pharmaceutical leader, boasts a deep portfolio of medicines across several therapeutic areas. The company is best-known for its work in immunology, with its two growth pillars, Skyrizi and Rinvoq, performing even better than management had anticipated. They should maintain sales growth for a while, and by the time they run into patent cliffs, the drugmaker will almost certainly have found new growth drivers. AbbVie is developing promising products, including an investigational weight-loss medicine, ABBV-295, that performed well in early stage studies.
The anti-obesity market is growing rapidly, and AbbVie's candidate could prove a highly differentiated **** et, as it can be administered monthly (the current leaders are taken weekly).
Let's consider two excellent stocks that fit the bill: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Both are Dividend Kings, or companies with at least 50 consecutive years of dividend increases. Here's why they are among my favorite stocks in this elite group to buy right now.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie, a pharmaceutical leader, boasts a deep portfolio of medicines across several therapeutic areas. The company is best-known for its work in immunology, with its two growth pillars, Skyrizi and Rinvoq, performing even better than management had anticipated. They should maintain sales growth for a while, and by the time they run into patent cliffs, the drugmaker will almost certainly have found new growth drivers. AbbVie is developing promising products, including an investigational weight-loss medicine, ABBV-295, that performed well in early stage studies.
The anti-obesity market is growing rapidly, and AbbVie's candidate could prove a highly differentiated **** et, as it can be administered monthly (the current leaders are taken weekly).
17 days ago
Just when we thought things were going in a good direction, tensions in the Middle East escalated again. If things worsen, it may eventually impact broader equities. Even if that doesn't happen, it's always useful for investors to buy shares in solid, dividend-paying corporations that can perform relatively well -- and continue raising their payouts -- regardless of economic conditions.
Let's consider two excellent stocks that fit the bill: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Both are Dividend Kings, or companies with at least 50 consecutive years of dividend increases. Here's why they are among my favorite stocks in this elite group to buy right now.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie, a pharmaceutical leader, boasts a deep portfolio of medicines across several therapeutic areas. The company is best-known for its work in immunology, with its two growth pillars, Skyrizi and Rinvoq, performing even better than management had anticipated. They should maintain sales growth for a while, and by the time they run into patent cliffs, the drugmaker will almost certainly have found new growth drivers. AbbVie is developing promising products, including an investigational weight-loss medicine, ABBV-295, that performed well in early stage studies.
The anti-obesity market is growing rapidly, and AbbVie's candidate could prove a highly differentiated ***** et, as it can be administered monthly (the current leaders are taken weekly).
Let's consider two excellent stocks that fit the bill: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ). Both are Dividend Kings, or companies with at least 50 consecutive years of dividend increases. Here's why they are among my favorite stocks in this elite group to buy right now.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
AbbVie, a pharmaceutical leader, boasts a deep portfolio of medicines across several therapeutic areas. The company is best-known for its work in immunology, with its two growth pillars, Skyrizi and Rinvoq, performing even better than management had anticipated. They should maintain sales growth for a while, and by the time they run into patent cliffs, the drugmaker will almost certainly have found new growth drivers. AbbVie is developing promising products, including an investigational weight-loss medicine, ABBV-295, that performed well in early stage studies.
The anti-obesity market is growing rapidly, and AbbVie's candidate could prove a highly differentiated ***** et, as it can be administered monthly (the current leaders are taken weekly).
26 days ago
After several years of underperforming the market, Iovance Biotherapeutics (NASDAQ: IOVA) is finally bouncing back. The biotech company's shares have soared 74% this year. However, the stock still looks pretty cheap -- it is trading for just under $5 apiece. And for what it's worth, several Wall Street **** ysts think it could rise even more. Its average price target (according to Yahoo! Finance) is $8.80. Should investors rush to buy the company's shares?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Iovance Biotherapeutics developed Amtagvi, an approved medicine for treating melanoma. Amtagvi is manufactured from patients' own cancer-fighting cells, which are harvested, grown in a lab, and then reinserted back into the patient. Amtagvi's sales are growing at a good clip. In the first quarter, Iovance Biotherapeutics' revenue (mostly from this product) increased 45% year over year to $71.4 million. Meanwhile, Iovance Biotherapeutics is making progress in regions outside the U.S. It earned approval for Amtagvi in Canada last year, and could see the medicine's sales improve meaningfully as it ramps up commercial efforts in the country.
Further, Iovance Biotherapeutics could obtain approval for Amtagvi in several other countries, including across the European Union. Launching the medicine in these regions would significantly expand its addressable opportunity, likely even more so than the Canadian market. Elsewhere, the company is making clinical progress. Iovance Biotherapeutics is developing Amtagvi for the treatment of endometrial cancer. The company also boasts several other pipeline candidates. Provided the biotech company can earn significant clinical wins over the next few years while also making solid commercial progress with Amtagvi, it could maintain the momentum it has had so far this year.
However, several factors could derail Iovance Biotherapeutics' plans, including the very real risk of clinical or regulatory setbacks every drugmaker faces. It has already encountered several. For instance, Iovance Biotherapeutics announced earlier this year that it was withdrawing its regulatory application for Amtagvi in the United Kingdom due to "procedural reasons," although it said it would resubmit it promptly. Beyond potential regulatory roadblocks, there is a much bigger issue with the Company. The medicines it develops are complex to manufacture and administer.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Iovance Biotherapeutics developed Amtagvi, an approved medicine for treating melanoma. Amtagvi is manufactured from patients' own cancer-fighting cells, which are harvested, grown in a lab, and then reinserted back into the patient. Amtagvi's sales are growing at a good clip. In the first quarter, Iovance Biotherapeutics' revenue (mostly from this product) increased 45% year over year to $71.4 million. Meanwhile, Iovance Biotherapeutics is making progress in regions outside the U.S. It earned approval for Amtagvi in Canada last year, and could see the medicine's sales improve meaningfully as it ramps up commercial efforts in the country.
Further, Iovance Biotherapeutics could obtain approval for Amtagvi in several other countries, including across the European Union. Launching the medicine in these regions would significantly expand its addressable opportunity, likely even more so than the Canadian market. Elsewhere, the company is making clinical progress. Iovance Biotherapeutics is developing Amtagvi for the treatment of endometrial cancer. The company also boasts several other pipeline candidates. Provided the biotech company can earn significant clinical wins over the next few years while also making solid commercial progress with Amtagvi, it could maintain the momentum it has had so far this year.
However, several factors could derail Iovance Biotherapeutics' plans, including the very real risk of clinical or regulatory setbacks every drugmaker faces. It has already encountered several. For instance, Iovance Biotherapeutics announced earlier this year that it was withdrawing its regulatory application for Amtagvi in the United Kingdom due to "procedural reasons," although it said it would resubmit it promptly. Beyond potential regulatory roadblocks, there is a much bigger issue with the Company. The medicines it develops are complex to manufacture and administer.
1 month ago
The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers lower fees and a higher dividend yield, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) spreads its holdings more evenly across the sector's biggest players.
Investors seeking pharmaceutical exposure in an ETF often have to choose between broad industry coverage and a more concentrated strategy. This comparison examines how IHE and PJP navigate the regulatory and research-heavy world of American drugmakers -- weighing fees, portfolio concentration, and long-term performance in a sector that can swing hard on a single clinical trial or FDA decision.
Metric
PJP
IHE
Investors seeking pharmaceutical exposure in an ETF often have to choose between broad industry coverage and a more concentrated strategy. This comparison examines how IHE and PJP navigate the regulatory and research-heavy world of American drugmakers -- weighing fees, portfolio concentration, and long-term performance in a sector that can swing hard on a single clinical trial or FDA decision.
Metric
PJP
IHE
1 month ago
By Chris Prentice and Amina Niasse
NEW YORK, July 1 (Reuters) - Millions more Americans will qualify for obesity medications at just $50 a month under a new Medicare program starting on Wednesday, bringing the highly effective drugs to people aged 65 and older at an affordable price.
The U.S. Centers for Medicare & Medicaid Services' 18-month trial program will offer for the first time Novo Nordisk's Wegovy and Eli Lilly's Foundayo and Zepbound as a weight-loss treatment alone.
Medicare, which also covers people with disabilities, has been barred from weight-loss coverage and had paid for the drugs only when prescribed for co-conditions like cardiovascular issues and severe fatty liver disease. Now the program offers three pathways for some Medicare subscribers to qualify for coverage.
Eligible patients are estimated in the single-digit millions, a U.S. official said recently. Wall Street **** ysts estimate that will amount to billions of dollars in revenue for the drugmakers.
NEW YORK, July 1 (Reuters) - Millions more Americans will qualify for obesity medications at just $50 a month under a new Medicare program starting on Wednesday, bringing the highly effective drugs to people aged 65 and older at an affordable price.
The U.S. Centers for Medicare & Medicaid Services' 18-month trial program will offer for the first time Novo Nordisk's Wegovy and Eli Lilly's Foundayo and Zepbound as a weight-loss treatment alone.
Medicare, which also covers people with disabilities, has been barred from weight-loss coverage and had paid for the drugs only when prescribed for co-conditions like cardiovascular issues and severe fatty liver disease. Now the program offers three pathways for some Medicare subscribers to qualify for coverage.
Eligible patients are estimated in the single-digit millions, a U.S. official said recently. Wall Street **** ysts estimate that will amount to billions of dollars in revenue for the drugmakers.
1 month ago
By Jonathan Stempel
June 24 (Reuters) - Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers and executives of fixing generic drug prices.
In a decision on Tuesday, Chief Judge Michael Shea of the federal district court in Connecticut said the states failed to show that Pfizer and its former Greenstone unit conspired with rivals between 2010 and 2014 to rig bids and allocate customers for six drug products.
These included generic versions of Eplerenone tablets for high blood pressure, Latanoprost drops for glaucoma, and four versions of Clindamycin phosphate for acne.
The states alleged that Greenstone executives exchanged more than 360 phone calls and text messages with the Swiss drugmaker Sandoz to coordinate anticompetitive activity.
June 24 (Reuters) - Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers and executives of fixing generic drug prices.
In a decision on Tuesday, Chief Judge Michael Shea of the federal district court in Connecticut said the states failed to show that Pfizer and its former Greenstone unit conspired with rivals between 2010 and 2014 to rig bids and allocate customers for six drug products.
These included generic versions of Eplerenone tablets for high blood pressure, Latanoprost drops for glaucoma, and four versions of Clindamycin phosphate for acne.
The states alleged that Greenstone executives exchanged more than 360 phone calls and text messages with the Swiss drugmaker Sandoz to coordinate anticompetitive activity.
1 month ago
By Jonathan Stempel
June 24 (Reuters) - Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers and executives of fixing generic drug prices.
In a decision on Tuesday, Chief Judge Michael Shea of the federal district court in Connecticut said the states failed to show that Pfizer and its former Greenstone unit conspired with rivals between 2010 and 2014 to rig bids and allocate customers for six drug products.
These included generic versions of Eplerenone tablets for high blood pressure, Latanoprost drops for glaucoma, and four versions of Clindamycin phosphate for acne.
The states alleged that Greenstone executives exchanged more than 360 phone calls and text messages with the Swiss drugmaker Sandoz to coordinate anticompetitive activity.
June 24 (Reuters) - Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers and executives of fixing generic drug prices.
In a decision on Tuesday, Chief Judge Michael Shea of the federal district court in Connecticut said the states failed to show that Pfizer and its former Greenstone unit conspired with rivals between 2010 and 2014 to rig bids and allocate customers for six drug products.
These included generic versions of Eplerenone tablets for high blood pressure, Latanoprost drops for glaucoma, and four versions of Clindamycin phosphate for acne.
The states alleged that Greenstone executives exchanged more than 360 phone calls and text messages with the Swiss drugmaker Sandoz to coordinate anticompetitive activity.
2 months ago
June 15 (Reuters) - Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capacity and research in the country.
Pharmaceutical companies including Eli Lilly, Pfizer, AstraZeneca and Roche have announced roughly $500 billion in U.S. investments as they seek to strengthen infrastructure, mitigate supply-chain risks and reassure investors.
Pfizer
Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.
GSK
Pharmaceutical companies including Eli Lilly, Pfizer, AstraZeneca and Roche have announced roughly $500 billion in U.S. investments as they seek to strengthen infrastructure, mitigate supply-chain risks and reassure investors.
Pfizer
Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.
GSK
2 months ago
June 15 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut prices or make medicines domestically.
Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.
Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Pfizer
Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.
Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Pfizer
2 months ago
President Trump on Friday announced that over 100 prescription medications would be added to his administration's direct-to-consumer drug platform, TrumpRx, the second expansion of the initiative in as many months.
"I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a new total of over 800 of the most commonly-used Prescription Drugs," Trump wrote on Truth Social.
"TrumpRx.gov will now provide clear, transparent, and DISCOUNTED offerings for FOUR OUT OF FIVE of every prescription filled by Americans," the president added.
TrumpRx debuted in February with 43 branded prescription drugs, offering medications that treat conditions such as asthma, infertility and obesity to consumers at varying discounted rates. The platform now features two lists of medications, one for branded medications called "presidential deals" and another for generic drugs called "standard prices."
It was built to facilitate Trump's "most favored nation" (MFN) policy, which is designed to lower the cost of prescription drugs for U.S. consumers by dictating that drugmakers cannot charge a price for a specific brand-name drug higher than the lowest net price paid by other developed nations.
"I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a new total of over 800 of the most commonly-used Prescription Drugs," Trump wrote on Truth Social.
"TrumpRx.gov will now provide clear, transparent, and DISCOUNTED offerings for FOUR OUT OF FIVE of every prescription filled by Americans," the president added.
TrumpRx debuted in February with 43 branded prescription drugs, offering medications that treat conditions such as asthma, infertility and obesity to consumers at varying discounted rates. The platform now features two lists of medications, one for branded medications called "presidential deals" and another for generic drugs called "standard prices."
It was built to facilitate Trump's "most favored nation" (MFN) policy, which is designed to lower the cost of prescription drugs for U.S. consumers by dictating that drugmakers cannot charge a price for a specific brand-name drug higher than the lowest net price paid by other developed nations.
2 months ago
Our ******* ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Abivax SA shares suffered a spectacular collapse on Tuesday, cratering as much as 40% in Paris and New York.
The clinical-stage drugmaker dropped highly anticipated Phase 3 maintenance data for its lead ulcerative colitis pill, obefazimod. The headline numbers revealed unmatched long-term efficacy, putting the company on a direct flight path to challenge big-pharma incumbents. However, the victory was instantly derailed by the appearance of scattered cancer cases concentrated exclusively in the high-dose cohort, spooking institutional investors and prompting an immediate, high-profile ******* yst downgrade.
The results from the global 44-week ABTECT maintenance study originally looked like a best-case scenario. Evaluating patients with moderately to severely active ulcerative colitis — many of whom were completely refractory, having failed multiple advanced biologic therapies — obefazimod proved to be an absolute clinical powerhouse. Patients on either the 25 mg or 50 mg once-daily oral doses achieved clinical remission rates of 50.8% and 51.3%, respectively. This stands in contrast to a meager 10.4% baseline for the placebo group, securing a placebo-adjusted remission rate of roughly 40%.
The financial wheels fell off, however, when investors opened the safety appendix. In the higher 50 mg treatment arm, investigators recorded individual diagnoses of prostate cancer, breast cancer, and colonic dysplasia — an abnormal cell progression that often acts as a precursor to malignant tumors. The high-dose cluster also flagged four separate non-melanoma skin cancer cases.
Abivax SA shares suffered a spectacular collapse on Tuesday, cratering as much as 40% in Paris and New York.
The clinical-stage drugmaker dropped highly anticipated Phase 3 maintenance data for its lead ulcerative colitis pill, obefazimod. The headline numbers revealed unmatched long-term efficacy, putting the company on a direct flight path to challenge big-pharma incumbents. However, the victory was instantly derailed by the appearance of scattered cancer cases concentrated exclusively in the high-dose cohort, spooking institutional investors and prompting an immediate, high-profile ******* yst downgrade.
The results from the global 44-week ABTECT maintenance study originally looked like a best-case scenario. Evaluating patients with moderately to severely active ulcerative colitis — many of whom were completely refractory, having failed multiple advanced biologic therapies — obefazimod proved to be an absolute clinical powerhouse. Patients on either the 25 mg or 50 mg once-daily oral doses achieved clinical remission rates of 50.8% and 51.3%, respectively. This stands in contrast to a meager 10.4% baseline for the placebo group, securing a placebo-adjusted remission rate of roughly 40%.
The financial wheels fell off, however, when investors opened the safety appendix. In the higher 50 mg treatment arm, investigators recorded individual diagnoses of prostate cancer, breast cancer, and colonic dysplasia — an abnormal cell progression that often acts as a precursor to malignant tumors. The high-dose cluster also flagged four separate non-melanoma skin cancer cases.
